All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Rintatolimod
Therapeutic Area: Infections and Infectious Diseases Product Name: Ampligen
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Aim ImmunoTech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 29, 2021
Details:
CHDR, will conduct and manage the proposed clinical study, titled “A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Activity of Repeated Intranasal Administration of Ampligen (Poly I:Poly C12U) in Healthy Subjects.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AKS-452
Therapeutic Area: Infections and Infectious Diseases Product Name: AKS-452
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Akston Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 01, 2020
Details:
TRACER will will provide regulatory services, oversight of local manufacturing contractors as well as Phase 1 Study preparation and clinical site management for Akston Biosciences' Phase 1 clinical testing in of its lead COVID-19 vaccine candidate, AKS-452.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): HP163
Therapeutic Area: Infections and Infectious Diseases Product Name: HP163
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 20, 2020
Details:
A recent publication in Nature Neuroscience reported that Hercules’ AhR inhibitor HP163 reduces viral replication in animals infected with Zika-virus and reduced microencephaly.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): K-NK-ID101
Therapeutic Area: Infections and Infectious Diseases Product Name: K-NK-ID101
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 17, 2020
Details:
The collaboration will study NK-cell biology in COVID-19 patients, the elimination of SARS-CoV-2 virus and virally infected cells by K-NK cells, and synergies between monoclonal antibodies, vaccines and K-NK cells.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 14, 2020
Details:
Saillant Therapeutics has discovered an innovative groundbreaking generic virus-inhibiting treatment platform based on activation of a cellular master regulator.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TR-C 19
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2020
Details:
VSY Biotechnology Research Center has developed a strong R&D program in various areas of biotechnology and is now proud to announce its latest achievement: TR-C 19, a drug to treat COVID-19.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Sonlicromanol
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2020
Details:
Company’s lead asset sonlicromanol may have potential as a repurposed treatment for PGE2-driven inflammatory consequences underlying severe COVID-19 disease.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: University of Queensland
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 09, 2020
Details:
The UQ team will partner with the Dutch company, Viroclinics Xplore, on the crucial pre-clinical studies.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): VSV∆G-SARS-CoV-2
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: IAVI
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 05, 2020
Details:
By working with Batavia Biosciences, IAVI intends to develop an end-to-end platform for flexible, low-cost production of epidemic preparedness vaccines, including vaccines against a group of viruses that cause hemorrhagic fevers and other emerging viral disease threats.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
